Tender detail
Conclusion of a non-exclusive discount agreement for Elafibranor for 2026–2028
Summary
DAK-Gesundheit intends to conclude medicine discount agreements with interested pharmaceutical companies for medicines containing Elafibranor (ATC A05AX06). The agreements will run from 1 December 2026 to 30 November 2028, but will end earlier if an exclusive agreement enters into force.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.